NZ512586A - Methods and compositions for treatment of cell proliferative disorders - Google Patents
Methods and compositions for treatment of cell proliferative disordersInfo
- Publication number
- NZ512586A NZ512586A NZ512586A NZ51258699A NZ512586A NZ 512586 A NZ512586 A NZ 512586A NZ 512586 A NZ512586 A NZ 512586A NZ 51258699 A NZ51258699 A NZ 51258699A NZ 512586 A NZ512586 A NZ 512586A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compositions
- acetylglucosamine
- treatment
- free
- g1cnac
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 229950006780 n-acetylglucosamine Drugs 0.000 abstract 3
- -1 N-acetylglucosamine monosaccharides Chemical class 0.000 abstract 2
- 239000000356 contaminant Substances 0.000 abstract 2
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 210000005170 neoplastic cell Anatomy 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 abstract 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 235000000346 sugar Nutrition 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Surgery (AREA)
- Materials Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/218,288 US6063911A (en) | 1993-12-01 | 1998-12-22 | Methods and compositions for treatment of cell proliferative disorders |
| PCT/US1999/030575 WO2000036918A1 (en) | 1998-12-22 | 1999-12-21 | Methods and compositions for treatment of cell proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ512586A true NZ512586A (en) | 2004-01-30 |
Family
ID=22814511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ512586A NZ512586A (en) | 1998-12-22 | 1999-12-21 | Methods and compositions for treatment of cell proliferative disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6063911A (enExample) |
| EP (1) | EP1139752B1 (enExample) |
| JP (1) | JP4795539B2 (enExample) |
| CN (1) | CN100488512C (enExample) |
| AT (1) | ATE294504T1 (enExample) |
| AU (1) | AU780248B2 (enExample) |
| CA (1) | CA2356087C (enExample) |
| DE (1) | DE69925156T2 (enExample) |
| ES (1) | ES2242448T3 (enExample) |
| HK (1) | HK1043507B (enExample) |
| IL (2) | IL143700A0 (enExample) |
| NO (1) | NO330033B1 (enExample) |
| NZ (1) | NZ512586A (enExample) |
| WO (1) | WO2000036918A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US5858350A (en) | 1993-12-01 | 1999-01-12 | Marine Polymer Technologies | Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system |
| US6743783B1 (en) * | 1993-12-01 | 2004-06-01 | Marine Polymer Technologies, Inc. | Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine |
| US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
| US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
| ID25921A (id) | 1997-04-28 | 2000-11-09 | Texas Biotechnology Corp | Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin |
| US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| US6545048B1 (en) * | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| EP1229934B1 (en) | 1999-10-01 | 2014-03-05 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| IL150311A0 (en) | 1999-12-31 | 2002-12-01 | Texas Biotechnology Corp | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US20050245451A1 (en) * | 2000-04-05 | 2005-11-03 | Pincus Matthew R | Peptides selectively lethal to malignant and transformed mammalian cells |
| TWI306760B (en) * | 2000-08-07 | 2009-03-01 | Abbott Lab | Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same |
| PL366419A1 (en) * | 2000-08-22 | 2005-01-24 | Boehringer Ingelheim Pharma Bmbh & Co.Kg | Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors |
| US7041657B2 (en) | 2001-02-12 | 2006-05-09 | Marine Polymer Technologies Inc. | Compositions and methods for modulation of vascular structure and/or function |
| DE10155076A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen |
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| EP1587424A4 (en) * | 2002-12-31 | 2012-01-25 | Marinepolymer Tech Inc | Bleeding Compounds and their uses |
| KR20050098250A (ko) * | 2003-01-17 | 2005-10-11 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 에너골리틱제를 사용한 양성 전립선 비대증의 치료 방법 |
| NZ542501A (en) * | 2003-02-24 | 2009-09-25 | Marinepolymer Tech Inc | Compositions comprising chitin or chitosan and use thereof |
| WO2004100991A1 (en) * | 2003-05-15 | 2004-11-25 | Universite Catholique De Louvain | Use of endothelin-1 antagonists for improving cancer therapy |
| EP1673134A4 (en) * | 2003-09-12 | 2007-03-21 | Marinepolymer Tech Inc | RECEIVING VASCULAR ACCESS IN HEMODIALYSIS PATIENTS |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| EP1734821A4 (en) * | 2004-04-14 | 2011-07-06 | Uab Research Foundation | ACTIVATORS OF HEXOSAMIN BINOSYNTHESIS AS AN INHIBITORS FOR INDUCED DAMAGE CAUSED BY ISCHEMIC SHOCK OR HEMORRHAGIC SHOCK |
| PL1899364T5 (pl) | 2005-05-17 | 2024-12-09 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| JP5709356B2 (ja) | 2006-01-13 | 2015-04-30 | アメリカ合衆国 | 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子 |
| US8871247B2 (en) * | 2007-02-19 | 2014-10-28 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
| AU2008269032B2 (en) | 2007-06-27 | 2013-12-05 | Novartis Ag | Complexes of IL-15 and IL-15Ralpha and uses thereof |
| US9539327B2 (en) * | 2007-11-26 | 2017-01-10 | The Research Foundation For The State University Of New York | Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells |
| NZ714757A (en) | 2009-08-14 | 2018-07-27 | Us Gov Health & Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| CA2796068C (en) | 2010-04-15 | 2022-07-19 | Marine Polymer Technologies, Inc. | Anti-bacterial applications of poly-n-acetylglucosamine nanofibers |
| MX356877B (es) | 2011-04-15 | 2018-06-19 | Marine Polymer Tech Inc | Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina. |
| GB201616087D0 (en) * | 2016-09-21 | 2016-11-02 | Tomalgae Cvba | Algae comprising therapeutic and/or nutritional agents |
| WO2019195851A1 (en) | 2018-04-06 | 2019-10-10 | Oncolyze, Inc. | Compositions for use in lysis of selective cancer cells |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1038367A (en) * | 1963-05-28 | 1966-08-10 | Beecham Group Ltd | Penicillin derivatives |
| US3988411A (en) * | 1974-02-11 | 1976-10-26 | American Cyanamid Company | Spinning and shaping poly-(N-acetyl-D-glucosamine) |
| US3989535A (en) * | 1974-02-11 | 1976-11-02 | American Cyanamid Company | Solution of poly(N-acetyl-D-glucosamine) |
| JPS55152705A (en) * | 1979-05-18 | 1980-11-28 | Mitsubishi Rayon Co Ltd | Preparation of water-soluble alkali chitin |
| US4378017A (en) * | 1980-03-21 | 1983-03-29 | Kureha Kagaku Kogyo Kabushiki Kaisha | Composite material of de-N-acetylated chitin and fibrous collagen |
| JPS5927826A (ja) * | 1982-08-10 | 1984-02-14 | Masuko Suzuki | 抗感染症剤 |
| US4803168A (en) * | 1983-09-01 | 1989-02-07 | Damon Biotech, Inc. | Microencapsulation with polymers |
| US4749620A (en) * | 1984-02-15 | 1988-06-07 | Massachusetts Institute Of Technology | Encapsulated active material system |
| GR862353B (en) * | 1985-09-23 | 1987-01-19 | Lilly Co Eli | Anti-tumor method and compounds |
| JPS62288602A (ja) * | 1986-06-06 | 1987-12-15 | Agency Of Ind Science & Technol | キトサン変性物粒子の製造方法 |
| US4942129A (en) * | 1987-07-28 | 1990-07-17 | Queen's University At Kingston | Multiple membrane microencapsulation |
| US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5008116A (en) * | 1988-11-14 | 1991-04-16 | Frederick Cahn | Immunostimulatory microsphere |
| US5071977A (en) * | 1989-05-10 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Plaque inhibiting oligosaccharide |
| US5116747A (en) * | 1989-08-11 | 1992-05-26 | University Of Waterloo | Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate |
| US5529914A (en) * | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
| JPH04334322A (ja) * | 1991-05-09 | 1992-11-20 | Unitika Ltd | 抗腫瘍剤 |
| US5382569A (en) * | 1991-05-16 | 1995-01-17 | Warner-Lambert Company | Endotherlin antagonists |
| CA2072395A1 (en) * | 1991-07-01 | 1993-01-02 | John T. Hunt | Bicyclic endothelin analogues |
| US5219749A (en) * | 1991-10-09 | 1993-06-15 | Institute For Molecular Biology & Biotechnology/Forth | Process for isolating and preparing purified chitin deacetylase |
| US5229123A (en) * | 1991-10-09 | 1993-07-20 | Hoffmann-La Roche Inc. | Antifungal agents |
| WO1993009176A2 (en) * | 1991-10-29 | 1993-05-13 | Clover Consolidated, Limited | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
| ES2164054T3 (es) * | 1991-11-05 | 2002-02-16 | Smithkline Beecham Corp | Antagonistas de receptores de endotelina. |
| IL100096A (en) * | 1991-11-20 | 1996-03-31 | Univ Ramot | Method for entrapment of active materials in chitosan |
| US5260002A (en) * | 1991-12-23 | 1993-11-09 | Vanderbilt University | Method and apparatus for producing uniform polymeric spheres |
| US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
| US5550110A (en) * | 1992-04-22 | 1996-08-27 | Warner-Lambert Company | Endothelin Antagonists II |
| WO1994003483A1 (en) * | 1992-07-30 | 1994-02-17 | Chiron Corporation | Endothelin receptor-binding compounds |
| TW394761B (en) * | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
| US5858350A (en) * | 1993-12-01 | 1999-01-12 | Marine Polymer Technologies | Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system |
| US5624679A (en) * | 1993-12-01 | 1997-04-29 | Marine Polymer Technologies, Inc. | Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers |
| US5622834A (en) * | 1993-12-01 | 1997-04-22 | Marine Polymer Technologies, Inc. | Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture |
| WO1996011927A1 (en) * | 1994-10-12 | 1996-04-25 | Abbott Laboratories | Endothelin antagonists |
| TW313568B (enExample) * | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| US5658943A (en) * | 1995-01-05 | 1997-08-19 | Warner-Lambert Company | Phenylalanine derivatives as endothelin antagonists |
| WO1996039122A1 (en) * | 1995-06-06 | 1996-12-12 | Marine Polymer Technologies, Inc. | POLY-β-1→4-N-ACETYLGLUCOSAMINE |
| AU6603996A (en) * | 1995-08-24 | 1997-03-19 | Warner-Lambert Company | Furanone endothelin antagonists |
| AU2529297A (en) * | 1996-04-10 | 1997-10-29 | Warner-Lambert Company | Ketoacid endothelin antagonists |
-
1998
- 1998-12-22 US US09/218,288 patent/US6063911A/en not_active Expired - Lifetime
-
1999
- 1999-12-21 CN CNB998163155A patent/CN100488512C/zh not_active Expired - Lifetime
- 1999-12-21 AT AT99968523T patent/ATE294504T1/de not_active IP Right Cessation
- 1999-12-21 JP JP2000589041A patent/JP4795539B2/ja not_active Expired - Lifetime
- 1999-12-21 EP EP99968523A patent/EP1139752B1/en not_active Expired - Lifetime
- 1999-12-21 IL IL14370099A patent/IL143700A0/xx active IP Right Grant
- 1999-12-21 NZ NZ512586A patent/NZ512586A/xx not_active IP Right Cessation
- 1999-12-21 HK HK02104737.8A patent/HK1043507B/zh not_active IP Right Cessation
- 1999-12-21 ES ES99968523T patent/ES2242448T3/es not_active Expired - Lifetime
- 1999-12-21 AU AU25919/00A patent/AU780248B2/en not_active Expired
- 1999-12-21 WO PCT/US1999/030575 patent/WO2000036918A1/en not_active Ceased
- 1999-12-21 CA CA002356087A patent/CA2356087C/en not_active Expired - Lifetime
- 1999-12-21 DE DE69925156T patent/DE69925156T2/de not_active Expired - Lifetime
-
2001
- 2001-06-12 IL IL143700A patent/IL143700A/en not_active IP Right Cessation
- 2001-06-20 NO NO20013071A patent/NO330033B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP4795539B2 (ja) | 2011-10-19 |
| EP1139752B1 (en) | 2005-05-04 |
| NO20013071D0 (no) | 2001-06-20 |
| AU2591900A (en) | 2000-07-12 |
| CA2356087A1 (en) | 2000-06-29 |
| US6063911A (en) | 2000-05-16 |
| AU780248B2 (en) | 2005-03-10 |
| IL143700A (en) | 2006-08-01 |
| ES2242448T3 (es) | 2005-11-01 |
| HK1043507B (zh) | 2009-12-24 |
| WO2000036918A9 (en) | 2000-11-23 |
| NO20013071L (no) | 2001-08-20 |
| DE69925156T2 (de) | 2006-02-16 |
| IL143700A0 (en) | 2002-04-21 |
| DE69925156D1 (de) | 2005-06-09 |
| CN1335749A (zh) | 2002-02-13 |
| CN100488512C (zh) | 2009-05-20 |
| CA2356087C (en) | 2009-02-17 |
| JP2003522732A (ja) | 2003-07-29 |
| NO330033B1 (no) | 2011-02-07 |
| HK1043507A1 (zh) | 2002-09-20 |
| ATE294504T1 (de) | 2005-05-15 |
| EP1139752A4 (en) | 2003-01-02 |
| WO2000036918A1 (en) | 2000-06-29 |
| EP1139752A1 (en) | 2001-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ512586A (en) | Methods and compositions for treatment of cell proliferative disorders | |
| Maita et al. | The primary structure of skeletal muscle myosin heavy chain: IV. Sequence of the rod, and the complete 1,938-residue sequence of the heavy chain | |
| US6559281B1 (en) | Non-naturally occurring synthetic lytic peptides | |
| CA2174325A1 (en) | Non-antigenic branched polymer conjugates | |
| CA2333145A1 (en) | Drug delivery system comprising a homeobox peptide and a non-peptide, non-nucleotide drug | |
| NZ337845A (en) | Non-antigenic branched polymer conjugates | |
| CA2263889A1 (en) | P-selectin ligand proteins | |
| WO1998040401A3 (en) | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics | |
| AU9174398A (en) | Peptides | |
| CA2323048A1 (en) | Poly(ethylene glycol) derivatives with proximal reactive groups | |
| NZ501386A (en) | Collagen from fish skin | |
| Arar et al. | Synthesis of oligonucleotide-peptide conjugates containing a KDEL signal sequence | |
| CA2147623A1 (en) | Novel p-selectin ligand protein | |
| PL342568A1 (en) | Deep-frozen article of food | |
| IL137256A0 (en) | Frozen food product | |
| DE59410132D1 (de) | Humanes zirkulierendes cytokin cc-1 | |
| AU4653301A (en) | Anti-freeze proteins, their production and use | |
| NZ230654A (en) | Anti-cell proliferative penta and hexa peptides | |
| Kikuchi et al. | The enzymic hydroxylation of protocollagen models | |
| WO1999065506A3 (en) | Cancer therapy with indolicidin or cationic peptides and their polymer conjugates | |
| Stanescu et al. | Characterization of a proteoglycan of high electrophoretic mobility | |
| CA2318432A1 (en) | The use of isolated domains of type iv collagen to modify cell and tissue interactions | |
| Casas-Finet et al. | Bacteriophage T4 gene 32 protein: modulation of protein-nucleic acid and protein-protein association by structural domains | |
| Lyon et al. | A rapid purification of bovine testicular hyaluronidase by chromatography on dermatan sulphate-substituted 1, 6-diaminohexane–sepharose 4B | |
| Yasuda et al. | Generation of basidiomycetous hyphal cell-aggregates by addition of the Arg-Gly-Asp motif-containing fragment of high-molecular-weight cell-adhesion protein MFBA derived from the basidiomycete Lentinus edodes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |